Advertisement #1
Home Authors Posts by David A. Roth, M.D.

David A. Roth, M.D.

David A. Roth, M.D. serves as the Chief Medical Officer for Syros Pharmaceuticals, Inc. He brings more than 20 years of experience in industry and academic clinical research with a strong track record of successful oncology and hematology drug development. Prior to Syros, he was Executive Vice President and Chief Medical Officer of Infinity Pharmaceuticals and, previously, interim Co-head of Clinical Development and Vice President of Early Development in Pfizer’s Oncology Business Unit. David joined Pfizer from Wyeth, where he held the roles of Assistant Vice President of Clinical Research & Development and Global Therapeutic Area Director of Hematology. While at Pfizer and Wyeth for over a decade, David contributed to the successful regulatory approval of several products, including Bosulif® (bosutinib), a dual Src/Abl tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia, Xyntha® and ReFacto AF® for the treatment of hemophilia A, and BeneFIX® for the treatment of hemophilia B. David also led the early development of Ibrance® (palbociclib), a CDK 4/6 inhibitor, which was awarded breakthrough status and subsequently received accelerated approval as a treatment for ER-positive, HER2-negative advanced breast cancer on a Phase 2 study. In addition to his extensive industry experience, David is an accomplished academic researcher and physician-scientist and was on the full-time faculty at Harvard Medical School and Beth Israel Deaconess Medical Center in the Division of Hematology/Oncology. He completed his fellowship in hematology and oncology at Tufts-New England Medical Center and his Internal Medicine residency at the New England Deaconess Hospital in Boston. David received his B.S. from the Massachusetts Institute of Technology and his M.D. from Harvard Medical School in the Harvard-M.I.T. Division of Health Sciences and Technology.